Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new drugs against neurodegenerative diseases

Current Medicinal Chemistry

Volumn 18, Issue 30, 2011, Pages 4568-4587

  Pisani, L ^a   Catto, M ^a   Leonetti, F ^a   Nicolotti, O ^a   Stefanachi, A ^a   Campagna, F ^a   Carotti, A ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Acetylcholinesterase inhibition; Alzheimer's disease; Monoamine oxidase inhibition; Multi target directed ligands; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE A2A RECEPTOR ANTAGONIST; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BROFAROMINE; CHOLINESTERASE INHIBITOR; CLORGYLINE; DONEPEZIL; DOPAMINE; IPRONIAZID; ISOCARBOXAZID; LAZABEMIDE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC AGENT; NITRIC OXIDE SYNTHASE; NORADRENALIN; PHENELZINE; PROTEIN BCL 2; PROTEIN BCL XL; RASAGILINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TOLOXATONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADJUVANT THERAPY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD PRESSURE; DEGENERATIVE DISEASE; DEPRESSION; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; DYSKINESIA; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; HEART RATE; HUMAN; HUNTINGTON CHOREA; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 80053462390     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797379302     Document Type: Review

References (171)

1. Petrelli, A.; Giordano, S. From single- to multi-target drugs in cancertherapy: when aspecificity becomes an advantage. Curr. Med. Chem., 2008, 15, 422-432. (Pubitemid 351472408)
2. Korcsmáros, T.; Szalay, M.S.; Böde, C.; Kovács, I. A.; Csermely, P. How todesign multi-target drugs: Target search options in cellular networks. ExpertOpin. Drug Disc., 2007, 2, 1-10.
3. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multipleligands. Drug Discov. Today, 2004, 9, 641-651.
4. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.;Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combatneurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
5. (a) Ekins, S.; Williams, A.J.; Krasowski, M.D.; Freundlich, J.S. In silicorepositioning of approved drugs for rare and neglected diseases. DrugDiscov. Today, 2011, 16, 298-310
6. (b)Ashburn, T.T.; Thor, K.B. Drugrepositioning: identifying and developing new uses for existing drugs. Nat.Rev. Drug Discov., 2004, 3, 673-683. (Pubitemid 39173508)
7. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drugdiscovery paradigm. J. Med. Chem., 2005, 48, 6523-6543. (Pubitemid 41504710)
8. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A.M. Molecular hybridization: a useful tool in the design of new drugprototypes. Curr. Med. Chem., 2007, 14, 1829-1852. (Pubitemid 47163402)
9. Strolin-Benedetti, M.; Tipton, K.F.; Whomsley, R. Amine oxidases andmonooxygenases in the in vivo metabolism of xenobiotic amines in humans:has the involvement of amine oxidases been neglected? Fundam. Clin. Pharmacol., 2007, 21, 467-479. (Pubitemid 47404324)
10. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure andmechanism of monoamine oxidases. Curr. Med. Chem., 2004, 11, 1983-1993.
11. Nandigama, R.K.; Edmondson, D.E. Structure-activity relations in theoxidation of phenethylamine analogues by recombinant human livermonoamine oxidase A. Biochemistry, 2000, 39, 15258-15265.
12. Grimsby, J.; lan, N.C.; Neve, R.; Chen, K.; Shih, J.C. Tissue distribution ofhuman monoamine oxidase-A and oxidase-B messenger-RNA. J.Neurochem., 1990, 55, 1166-1169.
13. Fowler, C.J.; Ross, S.B. Selective inhibitors of monoamine oxidase A and B:biochemical, pharmacological, and clinical properties. Med. Res. Rev., 1984, 4, 323-358. (Pubitemid 14073188)
14. Egashira, T. Studies on monoamine oxidase. XVIII. Enzymatic properties ofplacental monoamine oxidase. Jap. J. Pharmac., 1976, 26, 493-500.
15. Donnelly, C.H.; Murphy, D.L. Substrate- and inhibitor-related characteristicsof human platelet monoamine oxidase. Biochem. Pharmacol., 1977, 26, 852-858.
16. Saura, J.; Kettler, R.; Da Prada, M.; Richards, J.G. Quantitative enzymeradioautography with 3H-Ro 41-1049 and 3HRo 19-6327 in vitro:localization and abundance of MAO-A and MAO-B in rat CNS, peripheralorgans, and human brain. J. Neurosci., 1992, 12, 1977-1999.
17. (a) Youdim, M.B.; Edmondson, D.E.; Tipton, K.F. The therapeutic potentialof monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309
18. (b)Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safetyand future. Neurotoxicology, 2004, 25, 215-221.
19. Finberg, J.P.M.; Youdim, M.B.H. Selective MAO-A and MAO-B inhibitors:their mechanism of action and pharmacology. Neuropharmacology, 1983, 22, 441-446. (Pubitemid 13152056)
20. Fernandez, H.H.; Chen, J.J. Monoamine oxidase-B inhibition in thetreatment of Parkinson's disease. Pharmacotherapy, 2007, 27, S174-S185.
21. Wimbiscus, M.; Kostenko, O.; Malone, D. MAO inhibitors: risks, benefits, and lore. Cleve. Clin. J. Med., 2010, 77, 859-882.
22. Hauser, R.A. Early pharmacologic treatment in Parkinson's disease. Am. J.Manag. Care, 2010, 16, S100-S107.
23. Tuteja, N.; Ahmad, P.; Panda, B.B.; Tuteja, R. Genotoxic stress in plants:shedding light on DNA damage, repair and DNA repair helicases. Mut. Res-Rev. Mutat., 2009, 681, 134-149.
24. Jomova, K.; Vondrakova, D.; Lawson, M.; Valko, M. Metals, oxidativestress and neurodegenerative disorders. Mol. Cell. Biochem., 2010, 345, 91-104.
25. Gaeta, A.; Hider, R.C. The crucial role of metal ions in neurodegeneration:the basis for a promising therapeutic strategy. Br. J. Pharmacol., 2005, 146, 1041-1059. (Pubitemid 41786957)
26. Soto, C. Unfolding the role of protein misfolding in neurodegenerativediseases. Nat. Rev. Neurosci., 2003, 4, 49-60. (Pubitemid 37271088)
27. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress inneurodegenerative diseases. Nature, 2006, 443, 787-795. (Pubitemid 44622683)
28. Sterling, J.; Veinberg, A.; Lerner, D.; Goldenberg, W.; Levy, R.; Youdim, M.; Finberg, J. (R)(+)-N-propargyl-1-aminoindan (rasagiline) andderivatives: Highly selective and potent inhibitors of monoamine oxidase B.J. Neural Transm.-Supp., 1998, 52, 301-305.
29. (a) Finberg, J.P.; Lamensdorf, I.; Commissiong, J.W.; Youdim, M.B.H.Pharmacology and neuroprotective properties of rasagiline. J. NeuralTransm.-Supp., 1996, 48, 95-101 (Pubitemid 26423350)
30. (b) Finberg, J.P.; Lamensdorf, I.;Weinstock, M.; Schwartz, M.; Youdim, M.B.H. Pharmacology of rasagiline(N-propargyl-1R-aminoindan). Adv. Neurol., 1999, 80, 495-499
31. (c) Youdim, M.B.H.; Bakhle, Y.S. Monoamine oxidase: isoforms and inhibitors inParkinson's disease and depressive illness. Br. J. Pharmacol., 2006, 147, S287-S296 (Pubitemid 43077287)
32. (d) Youdim, M.B.H.; Edmondson, D.; Tipton, K.F. Thetherapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309.
33. Reynolds, G.P.; Riederer, P.; Sandler, M.; Jellinger, K.; Seemann, D.Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brainafter (L)-deprenyl administration. J. Neural Transm., 1978, 43, 271-277. (Pubitemid 9050088)
34. (a) Finberg, J.P.; Tenne, M.; Youdim, M.B.H. Tyramine antagonisticproperties of AGN 1135, an irreversible inhibitor of monoamine oxidase typeB. Br. J. Pharmacol., 1981, 73, 65-74 (Pubitemid 11104761)
35. (b) Simpson, L.L. Evidence thatdeprenyl, a type B monoamine oxidase inhibitor, is an indirectly actingsympathomimetic amine. Biochem. Pharmacol., 1978, 27, 1591-1595. (Pubitemid 8406839)
36. Maruyama, W.; Takahashi, T.; Youdim, M.B.H.; Naoi, M. The antiparkinsondrug, rasagiline, prevents apoptotic DNA damage induced byperoxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J.Neural Transm., 2002, 109, 467-481. (Pubitemid 34280405)
37. Heikkila, R.E.; Duvoisin, R.C.; Finberg, J.P.; Youdim, M.B.H. Prevention ofMPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selectiveinhibitors of monoamine oxidase-B. Eur. J. Pharmacol., 1985, 116, 313-317. (Pubitemid 16191823)
38. Maruyama, W.; Akao, Y.; Youdim, M.B.H.; Naoi, M. Neurotoxins induceapoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and(S)-aminoindan, rasagiline and TV1022. J. Neural Transm.-Supp., 2000, 60, 171-186. (Pubitemid 32037192)
39. Akao, Y.; Maruyama, W.; Shimizu, S.; Yi, H.; Nakagawa, Y.; Shamoto-Nagai, M.; Youdim, M.B.; Tsujimoto, Y.; Naoi, M. Mitochondrialpermeability transition mediates apoptosis induced by N-methyl-(R)-salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 andrasagiline, N-propargyl-1(R)- aminoindan. J. Neurochem., 2002, 82, 913-923.
40. Huang, W.; Chen, Y.; Shohami, E.; Weinstock, M. Neuroprotective effect ofrasagiline, a selective monoamine oxidase-B inhibitor, against closed headinjury in the mouse. Eur. J. Pharmacol., 1999, 366, 127-135. (Pubitemid 29080775)
41. Youdim, M.B.H.; Gross, A.; Finberg, J.P.M. Rasagiline [N-propargyl-1R(+)aminoindan], a selective and potent inhibitor of mitochondrialmonoamine oxidase B. Br. J. Pharmacol., 2001, 132, 500-506. (Pubitemid 32142364)
42. Youdim, M.B.H.; Weinstock, M. Molecular basis of neuroprotectiveactivities of rasagiline and the anti Alzheimer drug, TV3326, [(N-propargyl-(3R)-aminoindan-5-yl)-ethyl methyl carbamate]. Cell. Mol. Neurobiol., 2002, 21, 555-573. (Pubitemid 34538855)
43. (a) Weinreb, O.; Bar-Am, O.; Amit, T.; Chillag-Talmor, O.; Youdim, M.B.H.Neuroprotection via pro-survival protein kinase C isoforms associated withBcl-2 family members. FASEB J., 2004, 18, 1471-1473 (Pubitemid 39561618)
44. (b) Tatton, W.G.;Chalmers-Redman, R.M.; Ju, W.J.; Mammen, M.; Carlile, G.W.; Pong, A.W.; Tatton, N.A. Propargylamines induce antiapoptotic new proteinsynthesis inserum-and nerve growth factor(NGF)-withdrawn, NGFdifferentiatedPC-12 cells. J. Pharmacol. Exp. Ther., 2002, 301, 753-764 (Pubitemid 34429993)
45. (c)Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M. B. Regulation of Bcl-2family proteins, neurotrophic factors, and APP processing in the neurorescueactivity of propargylamine. FASEB J., 2005, 19, 1899-1901. (Pubitemid 41598788)
46. (a) Maruyama, W.; Akao, Y.; Youdim, M.B.H.; Davis, B.A.; Naoi, M.Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3- phosphatedehydrogenase induced by an endogenous dopaminergic neurotoxin, Nmethyl-(R)-salsolinol. J. Neurochem., 2001, 78, 727-735 (Pubitemid 32777974)
47. (b) Youdim, M.B.H. Rasagiline: an anti-Parkinson drug with neuroprotective activity.Expert Rev. Neurother., 2003, 3, 737-749. (Pubitemid 37462173)
48. (a) Yogev-Falach, M.; Amit, T.; Bar-Am, O.; Youdim, M.B.H. Theimportance of propargylamine moiety in the anti-Parkinson drug rasagilineand its derivatives for MAPK-dependent amyloid precursor proteinprocessing. FASEB J., 2003, 17, 2325-2327 (Pubitemid 39561481)
49. (b) Bar-Am, O.; Yogev-Falach, M.; Amit, T.; Sagi, Y.; Youdim, M.B.H. Regulation of protein kinase C bythe anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, invivo. J. Neurochem., 2004, 89, 1119-1125. (Pubitemid 38715829)
50. (a) Esch, F.S.; Keim, P.S.; Beattie, E.C.; Blacher, R.W.; Culwell, A.R.;Oltersdorf, T.; McClure, D.; Ward, P.J. Cleavage of amyloid beta peptideduring constitutive processing of its precursor. Science, 1990, 248, 1122-1124
51. (b) Sisodia, S.S.; Koo, E.H.; Beyreuther, K.; Unterbeck, A.; Price, D.L.Evidence that beta amyloid protein in Alzheimer's disease is not derived bynormal processing. Science, 1990, 248, 492-495.
52. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B.H. The neuroprotectivemechanism of 1-(R)-aminoindan, the major metabolite of the antiparkinsoniandrug rasagiline. J. Neurochem., 2010, 112, 1131-1137.
53. Chen, J.J.; Swope, D.M. ; Dashtipour, K. Comprehensive review ofrasagiline, a second-generation monoamine oxidase inhibitor, for thetreatment of Parkinson's disease. Clin. Ther., 2007, 29, 1825-1849. (Pubitemid 350212811)
54. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Z.Psychiat., 1907, 64, 146-148.
55. Querfurth, H.W.; LaFerla, F.M. Mechanisms of disease: Alzheimer'sdisease. New Engl. J. Med., 2010, 362, 329-344.
56. Sivaprakasam, K. Towards a unifying hypothesis of Alzheimer's disease:cholinergic system linked to plaques, tangles and neuroinflammation. Curr.Med. Chem., 2006, 13, 2179-2188. (Pubitemid 44132608)
57. Bolognesi, M.L.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Progress inacetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin. Ther.Pat., 2006, 16, 811-823. (Pubitemid 43949964)
58. Fisher, A.; Michaelson, D.M.; Brandeis, R.; Haring, R.; Chapman, S.; Pittel, Z. M1 muscarinic agonists as potential disease-modifying agents inAlzheimer's disease. Rationale and perspectives. Ann. N. Y. Acad. Sci., 2000, 920, 315-320. (Pubitemid 32056587)
59. Inestrosa, N.C.; Dinamarca, M.C.; Alvarez, A. Amyloid-cholinesterase interactions. FEBS J., 2008, 275, 625-632.
60. Martorana, A.; Esposito, Z.; Koch, G. Beyond the cholinergic hypothesis: docurrent drugs work in Alzheimer's disease? CNS Neurosci. Ther., 2010, 16, 235-245.
61. Frisardi, V.; Solfrizzi, V.; Imbimbo, P.B.; Capurso, C.; D'Introno, A.;Colacicco, A.M.; Vendemiale, G.; Seripa, D.; Pilotto, A.; Capurso, A.;Panza, F. Towards disease-modifying treatment of Alzheimer's disease:drugs targeting β-Amyloid. Curr. Alzheimer Res., 2010, 7, 40-55.
62. Evin, G.; Kenche, V.B. BACE inhibitors as potential therapeutics forAlzheimer's disease. Recent Pat. CNS Drug Discov., 2007, 2, 188-199. (Pubitemid 350200291)
63. Lundkvist, J.; Naslund, J. Gamma-secretase: a complex target forAlzheimer's disease. Curr. Opin. Pharmacol., 2007, 7, 112-118. (Pubitemid 46238041)
64. Mason, J.M.; Kokkoni, N.; Stott, K.; Doig, A.J. Design strategies for antiamyloidagents. Curr. Opin. Struc. Biol., 2003, 13, 526-532.
65. Lemere, C.A.; Masliah, E. Can Alzheimer disease be prevented by amyloid-βimmunotherapy? Nat. Rev. Neurol., 2010, 6, 108-119.
66. Sun, A.Y.; Chen, Y.M. Oxidative stress and neurodegenerative disorders. J.Biomed. Sci., 1998, 5, 401-414. (Pubitemid 28559104)
67. (a) Delumeau, J.C.; Bentué-Ferrer, D.; Gandon, J.M.; Amrein, R.; Belliard, S.; Allain, H. Monoamine oxidase inhibitors, cognitive functions andneurodegenerative diseases. J. Neural Transm. Suppl., 1994, 41, 259-266 (Pubitemid 24215700)
68. (b)Naoi, M.; Maruyama, W.; Akao, Y.; Yi, H.; Yamaoka, T. Involvement oftype A monoamine oxidase in neurodegeneration: regulation ofmitochondrial signaling leading to cell death or neuroprotection. J. NeuralTransm. Suppl., 2006, 71, 67-77. (Pubitemid 351412108)
69. Saura, J.; Luque, J.M.; Cesura, A.M.; Da Prada, M.; Chan-Palay, V.; Huber, G.; Loffler, J.; Richards, J.G. Increased monoamine oxidase B activity inplaque-associated astrocytes of Alzheimer brains revealed by quantitativeenzyme radioautography. Neuroscience, 1994, 62, 15-30. (Pubitemid 24287342)
70. (a) Van der Schyf, C.J.; Geldenhuys, W.J.; Youdim, M.B.H. Multifunctionaldrugs with different CNS targets for neuropsychiatric disorders. J.Neurochem., 2006, 99, 1033-1048 (Pubitemid 44655271)
71. (b) Youdim, M.B.H.; Buccafusco, J.J.Multi-functional drugs for various CNS targets in the treatment ofneurodegenerative disorders. Trends Pharm. Sci., 2005, 26, 27-35. (Pubitemid 40052707)
72. Fink, D.M.; Palermo, M.G.; Bores, G.M.; Huger, F.P.; Kurys, B.E.;Merriman, M.C.; Olsen, G.E.; Petko, W.; O'Malley, G.J. Imino 1, 2, 3, 4-tetrahydrocyclopent [b]indole carbamates as dual inhibitors ofacetylcholinesterase and monoamine oxidase. Bioorg. Med. Chem. Lett., 1996, 6, 625-630. (Pubitemid 26107892)
73. O'Malley, G.J.; Bores, G.; Huger, F.; Kuris, B.E.; Merriman, M.C.; Olsen, G.; Petko, W.; Palermo, M.G. Abstract of the 205th American ChemicalSociety National Meeting 1993, MEDI, abstract.
74. Hilgert, M.; Nöldner, M.; Chatterjee, S.S.; Klein, J. KA-672 inhibits rat brainacetylcholinesterase in vitro but not in vivo. Neurosci. Lett., 1999, 263, 193-196. (Pubitemid 29158961)
75. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.;Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalizedcoumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med.Chem., 2000, 43, 4747-4758. (Pubitemid 32002686)
76. Bruhlmann, C.; Ooms, F.; Carrupt, P.A.; Testa, B.; Catto, M.; Leonetti, F.;Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors ofacetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44, 3195-3198. (Pubitemid 32862350)
77. Pisani, L.; Catto, M.; Giangreco, I.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Cellamare, S.; Carotti, A. Design, synthesis and biological evaluation ofcoumarin derivatives tethered to an edrophonium-like fragment as highlypotent and selective dual binding site acetylcholinesterase inhibitors.ChemMedChem, 2010, 5, 1616-1630.
78. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.;Zekany, A.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.;Krais, B.; Chorev, M.; Youdim, M.B.H.; Weinstock, M. Novel dualinhibitors of AChE and MAO derived from hydroxy aminoindan andphenethylamine as potential treatment for Alzheimer's disease. J. Med.Chem., 2002, 45, 5260-5279. (Pubitemid 35429165)
79. Weinstock, M.; Gorodetsky, E.; Wang, R.H.; Fross, A.; Weinreb, O.;Youdim, M.B.H. Limited potentiation of blood pressure response to oraltyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 inconscious rabbits. Neuropharmacology, 2002, 43, 999-1005. (Pubitemid 35341235)
80. Weinstock, M.; Gorodetsky, E.; Poltyrev, T.; Gross, A.; Sagi, Y.; Youdim, M.B.H. A novel cholinesterase and brain-selective monoamine oxidaseinhibitor for the treatment of dementia comorbid with depression andParkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 555-561. (Pubitemid 36645054)
81. Sagi, Y.; Weinstock, M.; Youdim, M.B.H. Attenuation of MPTP-induceddopaminergic neurotoxicity by TV3326, a cholinesterase- monoamineoxidase inhibitor. J. Neurochem., 2003, 86, 290-297. (Pubitemid 36842429)
82. Sagi, Y.; O. Weinreb, O.; Weinstock, M.; Youdim, M.B.H. Neuroprotectiveand neurorescue properties of rasagiline and TV3326 in MPTP model ofParkinson's disease. Neural Plasticity, 2001, 8, 197-198.
83. Weinstock, M.; Kirschbaum-Slager, N.; Lazarovici, P.; Bejar, C.; Youdim, M.B.H.; Shoham, S. Neuroprotective effects of novel cholinesteraseinhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. N.Y. Acad. Sci., 2001, 939, 148-161. (Pubitemid 32620064)
84. Naoi, M.; Maruyama, W. Monoamine oxidase inhibitors as neuroprotectiveagents in age-dependent neurodegenerative disorders. Curr. Pharm. Design, 2010, 16, 2799-2817.
85. Gökhan, N.; Yesilada, A.; Uçar, G.; Erol, K.; Bilgin, A. 1-N-Substitutedthiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation asMAO inhibitors. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 362-371. (Pubitemid 37127992)
86. Uçar, G.; Gökhan, N.; Yesilada, A.; Bilgin, A.A. 1-N-Substitutedthiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase andselective monoamine oxidase B inhibitors for the treatment of Parkinson'sand Alzheimer's diseases. Neurosci. Lett., 2005, 382, 327-331. (Pubitemid 40733646)
87. (a) Bruhlmann, C.; Marston, A.; Hostettmann, K.; Carrupt, P.A.; Testa, B.Screening of non-alkaloidal natural compounds as acetylcholinesteraseinhibitors. Chem. Biodivers., 2004, 1, 819-829
88. (b) Gnerre, C.; Thull, U.;Gaillard, P.; Carrupt, P.-A.; Testa, B.; Fernandes, E.; Silva, F.; Pinto, M.;Pinto, M.M.M.; Wolfender, J.-L.; Hostettmann, K.; Cruciani, G. Natural andsynthetic xanthones as monoamine oxidase inhibitors: biological assay and3D-QSAR. Helv. Chim. Acta, 2001, 84, 552-570. (Pubitemid 32299308)
89. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol.Neurosurg. Psychiatry, 2008, 79, 368-376. (Pubitemid 351441488)
90. Allain, H.; Bentué-Ferrer, D.; Akwa, Y. Disease-modifying drugs andParkinson's disease. Prog. Neurobiol., 2008, 84, 25-39.
91. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.-Y.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α-Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
92. Oueslati, A.; Fournier, M.; Lashuel, H.A. Role of post- translationalmodifications in modulating the structure, function and toxicity of alphasynuclein:implications for Parkinson's disease pathogenesis and therapies.Prog. Brain Res., 2010, 183, 115-145.
93. Norris, E.H.; Giasson, B.I.; Ischiropoulos, H.; Lee, V.M. Effects of oxidativeand nitrative challenges on alpha-synuclein fibrillogenesis involve distinctmechanisms of protein modifications. J. Biol. Chem., 2003, 278, 27230-27240. (Pubitemid 36876880)
94. Wang, X.; Moualla, D.; Wright, J.A.; Brown, D.R. Copper binding regulatesintracellular alpha-synuclein localisation, aggregation and toxicity. J.Neurochem., 2010, 113, 704-714.
95. Bisaglia, M.; Tessari, I.; Mammi, S.; Bubacco, L. Interaction between alphasynucleinand metal ions, still looking for a role in the pathogenesis ofParkinson's disease. Neuromol. Med., 2009, 11, 239-251.
96. Lv, Z.; Jiang, H.; Xu, H.; Song, N.; Xie, J. Increased iron levels correlatewith the selective nigral dopaminergic neuron degeneration in Parkinson'sdisease. J. Neural Transm., 2011, 118, 361-369.
97. Allsop, D.; Mayes, J.; Moore, S.; Masad, A.; Tabner, B.J. Metal-dependentgeneration of reactive oxygen species from amyloid proteins implicated inneurodegenerative disease. Biochem. Soc. Trans., 2008, 36, 1293-1298.
98. Zecca, L.; Youdim, M.B.H.; Riederer, P.; Connor J.R.; Crichton, R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci., 2004, 5, 863-873. (Pubitemid 39482155)
99. Zheng, H.; Weiner, L.M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z.I.;Warshawsky, A.; Youdim, M.B.H.; Fridkin, M. Design, synthesis, andevaluation of novel bifunctional iron-chelators as potential agents forneuroprotection in Alzheimer's, Parkinson's, and other neurodegenerativediseases. Bioorg. Med. Chem., 2005, 13, 773-783. (Pubitemid 40093620)
100. Ben Shachar, D.B.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M.B.H. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology, 2004, 46, 254-263. (Pubitemid 37532833)
101. Zheng, H.; Gal, S.; Weiner, L.M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M.B.H. Novel multifunctional neuroprotective iron chelatormonoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitrostudies on antioxidant activity, prevention of lipid peroxide formation andmonoamine oxidase inhibition. J. Neurochem., 2005, 95, 68-78. (Pubitemid 41384426)
102. Youdim, M.B.H.; Fridkin, M.; Zheng, H. Bifunctional drug derivatives ofMAO-B inhibitor rasagiline and iron chelator VK-28 as a more effectiveapproach to treatment of brain ageing and ageing neurodegenerative diseases.Mech. Ageing Dev., 2005, 126, 317-326. (Pubitemid 40038353)
103. (a) Tatton, W.; Chalmers-Redman, R.; Tatton, N. Neuroprotection bydeprenyl and other propargylamines: glyceraldehyde-3-phosphatedehydrogenase rather than monoamine oxidase B. J. Neural Transm., 2003, 110, 509-515 (Pubitemid 36543282)
104. (b) Maruyama, W.; Youdim, M.B.H.; Naoi, M. Antiapoptoticproperties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical(S)-isomer, TV1022. Ann. N. Y. Acad. Sci., 2001, 939, 320-329.
105. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H.; Fridkin, M.;Youdim, M.B.H. Therapeutic targets and potential of the novel brainpermeablemultifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem., 2007, 100, 490-502. (Pubitemid 46016026)
106. Zheng, H.; Youdim, M.B.H.; Fridkin, M. Site-activated chelators targetingacetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACSChem. Biol., 2010, 5, 603-610.
107. Lee, M.H.; Lin, R.D.; Shen, L.Y.; Yang, L.L.; Yen, K.Y.; Hou, W.C.Monoamine oxidase B and free radical scavenging activities of naturalflavonoids in melastoma candidum D. Don. J. Agric. Food Chem., 2001, 49, 5551-5555.
108. Chimenti, F.; Cottiglia, F.; Bonsignore, L.; Casu, L.; Casu, M.; Floris, C.;Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.;Alcaro, S.; Ortuso, F.; Trombetta, G.; Loizzo, A.; Guarino, I. Quercetin asthe active principle of Hypericum hircinum exerts a selective inhibitoryactivity against MAO-A: Extraction, biological analysis, and computationalstudy. J. Nat. Prod., 2006, 69, 945-949. (Pubitemid 44166270)
109. Herraiz, T.; Guillén, H. Inhibition of the bioactivation of the neurotoxinMPTP by antioxidants, redox agents and monoamine oxidase inhibitors.Food Chem. Toxicol., 2011, 49, 1773-1781.
110. Ogata, M.; Hoshi, M.; Urano, S.; Endo, T. Antioxidant activity of eugenoland related monomeric and dimeric compounds. Chem. Pharm. Bull., 2000, 48, 1467-1469.
111. Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M. Eugenol and its structural analogsinhibit monoamine oxidase A and exhibit antidepressant-like activity.Bioorg. Med. Chem., 2005, 13, 4777-4788. (Pubitemid 40848356)
112. Moncada, S.; Palmer, R.M.J.; Higgs, E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43, 109-142.
113. Misra, M.K.; Sarwat, M.; Bhakuni, P.; Tuteja, R.; Tuteja, N. Oxidative stressand ischemic myocardial syndromes. Med. Sci. Monit., 2009, 15, RA209-219.
114. (a) Novo, E.; Parola, M. Redox mechanisms in hepatic chronic wound healingand fibrogenesis. Fibrogenesis Tissue Repair, 2008, 1, 5
115. (b) Brzozowski, M.J.; Alcantara, S.L.; Iravani, M.M.; Rose, S.; Jenner, P. The effect of nNOSinhibitors on toxin-induced cell death in dopaminergic cell lines depends onthe extent of enzyme expression. Brain Res., 2011, 1404, 21-30
116. (c) Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol., 1996, 271, C1424-1437.
117. Tuteja, N.; Chandra, M.; Tuteja, R.; Misra, M.K. Nitric oxide as a uniquebioactive signaling messenger in physiology and pathophysiology. J.Biomed. Biotech., 2004, 4, 227-237. (Pubitemid 40128959)
118. Silverman, R.B. Design of selective neuronal nitric oxide synthase inhibitorsfor the prevention and treatment of neurodegenerative diseases. Acc. Chem.Res., 2009, 42, 439-451.
119. (a) Cruces, M.A.; Elorriaga, C.; Fernandez-Alvarez, E.; Lopez Chico, M.T.;Nieto Lopez, O. Acetylenic and allenic derivatives of 2-(1-methylindolyl) methylamine as selective inhibitors of the monoamineoxidases A and B. Farmaco Sci., 1988, 43, 567-573 (Pubitemid 18261461)
120. (b) Cruces, M.A.;Elorriaga, C.; Fernandez-Alvarez, E. Acetylenic and allenic derivatives of 2-(5-methoxyindolyl) and 2-(5-hydroxyindolyl) methylamines: synthesis and invitro evaluation as monoamine oxidase inhibitors. Eur. J. Med. Chem., 1991, 26, 33-41
121. (c) Avila, M.; Balsa, M.D.; Fernandez-Alvarez, E.; Tipton, K. F.;Unzeta, M. The effect of side-chain substitution at positions 2 and 3 of theheterocyclic ring of N-acetylenic analogues of tryptamine as monoamineoxidase inhibitors. Biochem. Pharmacol., 1993, 45, 2231-2237 (Pubitemid 23171084)
122. (d) Balsa, D.;Fernandez-Alvarez, E.; Tipton, K.F.; Unzeta, M. Monoamine oxidaseinhibitory potencies and selectivities of 2-[N-(2-propynyl)-aminomethyl]- 1-methyl indole derivatives. Biochem. Soc. Trans., 1991, 19, 215-218.
123. Perez, V.; Marco, J.L.; Fernandez-Alvarez, E.; Unzeta, M. Relevance of abenzyloxy group in 2-indolyl methylamines in the selective MAO-Binhibition. Br. J. Pharmacol., 1999, 127, 869-876. (Pubitemid 29295345)
124. (a) Perez, V.; Unzeta, M. PF9601N [N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP induced depletionof striatal dopamine levels in C57/BL mice. Neurochem. Intern., 2003, 42, 221-229 (Pubitemid 35335694)
125. (b) Cutillas, B.; Ambrosio, S.; Unzeta, M. Neuroprotective effect ofthe monoamine oxidase inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine] on rat nigral neurons after 6-OH-DA striatallesion. Neurosci. Lett., 2002, 329, 165-168 (Pubitemid 34880064)
126. (c) Sanz, E.; Quintana, A.;Battaglia, V.; Toninello, A.; Hidalgo, J.; Ambrosio, S.; Valoti, M.; Marco, J.L.; Tipton, K.F.; Unzeta, M. Anti-apoptotic effect of MAO-B inhibitorPF9601N [N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine] is mediatedby p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergiccells. J. Neurochem., 2008, 105, 2404-2417. (Pubitemid 351782267)
127. Battaglia, V.; Sanz, E.; Salvi, M.; Unzeta, M.; Toninello, A. Protective effectof N-(2-propynyl)-2-(5-benzyloxy-indolyl)methylamine (PF9601N) onmitochondrial permeability transition. Cell. Mol. Life Sci., 2006, 63, 1440-1448. (Pubitemid 43939023)
128. Bellik, L.; Dragoni, S.; Pessina, F.; Sanz, E.; Unzeta, M.; Valoti, M.Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment ofits ability to interact with reactive nitrose species. Acta Biochim. Pol., 2010, 57, 235-239.
129. Prins, L.H.A.; Petzer, J.P.; Malan, S.F. Synthesis and in vitro evaluation ofpteridine analogues as monoamine oxidase B and nitric oxide synthaseinhibitors. Bioorg. Med. Chem., 2009, 17, 7523-7530.
130. Xu, K.Y.; Huso, D.L.; Dawson, T.M.; Bredt, D.S.; Becker, L.C. Nitric oxidesynthase in cardiac sarcoplasmic reticulum. Proc. Natl. Acad. Sci. USA, 1999, 96, 657-662. (Pubitemid 29061264)
131. Herraiz, T.; Aran, V. J.; Guillen, H. Nitroindazole compounds inhibit theoxidative activation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine(MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamineoxidase (MAO). Free Radical Res., 2009, 43, 975-984.
132. Castagnoli, K.; Palmer, S.; Anderson, A.; Bueters, T.; Castagnoli, N.Jr. Theneuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits themonoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Chem. Res. Toxicol., 1997, 10, 364-368. (Pubitemid 27176296)
133. Thomas, B.; Saravanan, K.S.; Mohanakumar, K.P. In vitro and in vivoevidences that antioxidant action contributes to the neuroprotective effects ofthe neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem. Int., 2008, 52, 990-1001.
134. Babbedge, R.C.; Bland-Ward, P.A.; Hart, S.L.; Moore, P.K. Inhibition of ratcerebellar nitric oxide synthase by 7-nitroindazole and related substitutedindazoles. Br. J. Pharmacol., 1993, 110, 225-228. (Pubitemid 23257783)
135. Doraiswamy, P.M. Non-cholinergic strategies for treating and preventingAlzheimer's disease. CNS Drugs, 2002, 16, 811-824. (Pubitemid 35440615)
136. Marx, J. Neurodegenerative disease: searching for drugs that combatAlzheimer's. Science, 1996, 273, 50.
137. Pasinetti, G.M. From epidemiology to therapeutic trials with antiinflammatorydrugs in Alzheimer's disease: the role of NSAIDs andcyclooxygenase in beta-amyloidosis and clinical dementia. J. Alzheimer'sDis., 2002, 4, 435-445. (Pubitemid 35397809)
138. Aisen, P.S.; Schafer, K.A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K.L.; Farlow, M.R.; Jin, S.; Thomas, R.G.; Thal, L.J. Effects of rofecoxib ornaproxen vs placebo on Alzheimer disease progression: a randomizedcontrolled trial. JAMA, 2003, 289, 2819-2826. (Pubitemid 37430117)
139. Gökhan-Kelekçi, N.; Yabanoǧlu, S.; Küpeli, E.; Salg?n, U.; Özgen, Ö.; Uçar, G.; Yeşilada, E.; Kendi, E.; Yeşilada, A.; Bilgin, A.A. A new therapeuticapproach in Alzheimer disease: Some novel pyrazole derivatives as dualMAO-B inhibitors and anti-inflammatory analgesics. Bioorg. Med. Chem., 2007, 15, 5775-5786. (Pubitemid 47043476)
140. Guigoni, C.; Aubert, I.; Li, Q.; Gurevich, V.V.; Benovic, J.L.; Ferry, S.;Mach, U.; Stark, H.; Leriche, L.; Hakansson, K.; Bioulac, B.H.; Gross, C.E.;Sokoloff, P.; Fisone, G.; Gurevich, E.V.; Bloch, B.; Bezard, E. Pathogenesisof levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.Parkinsonism Relat. D., 2005, 1, S25-S29. (Pubitemid 40693574)
141. Chen, J.F.; Xu, K.; Petzer, J.P.; Staal, R.; Xu, Y.H.; Beilstein, M.; Sonsalla, P.K.; Castagnoli, K.; Castagnoli, N.Jr.; Schwarzschild, M.A.Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in amodel of Parkinson's disease. J. Neurosci., 2001, 21, RC143.
142. Bibbiani, F.; Oh, J.D.; Petzer, J.P.; Castagnoli, N.Jr.; Chen, J.F.;Schwarzschild, M.A.; Chase, T.N. A2A antagonist prevents dopamineagonist-induced motor complications in animal models of Parkinson'sdisease. Exp. Neurol., 2003, 184, 285-294. (Pubitemid 37444038)
143. (a) Schwarzschild, M.A.; Agnati, L.; Fuxe, K.; Chen, J.F.; Morelli, M.Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci., 2006, 29, 647-654 (Pubitemid 44602262)
144. (b) Xu, K.; Bastia, E.; Schwarzschild, M. Therapeuticpotential of adenosine A(2A) receptor antagonists in Parkinson's disease.Pharmacol. Ther., 2005, 105, 267-310. (Pubitemid 40297894)
145. (a) Saura, J.; Richards, J.G.; Mahy, N. Differential age-related changes ofMAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol.Aging, 1994, 15, 399-408 (Pubitemid 24241808)
146. (b) Fowler, J.S.; Volkow, N.D.; Wang, G.-J.;Logan, J.; Pappas, N.; Shea, C.; Macgregor, R. Age-related increases in brainmonoamine oxidase B in living healthy human subjects. Neurobiol. Aging, 1997, 18, 431-435. (Pubitemid 27435085)
147. Jacobson, K.A.; Gallo-Rodriguez, C.; Melman, N.; Fischer, B.; Maillard, M.;van Bergen, A.; van Galen, P.J.; Karton, Y. Structure-activity relationshipsof 8-styrylxanthines as A2-selective adenosine antagonists. J. Med. Chem., 1993, 36, 1333-1342. (Pubitemid 23164489)
148. Chen, J.F.; Steyn, S.; Staal, R.; Petzer, J.P.; Xu, K.; Van Der Schyf, C.J.;Castagnoli, K.; Sonsalla, P.K.; Castagnoli, N.Jr.; Schwarzschild, M.A. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dualactions of monoamine oxidase inhibition and A2A receptor antagonism. J. Biol. Chem., 2002, 277, 36040-36044.
149. Petzer, J.P.; Steyn, S.; Castagnoli, K.P.; Chen, J.F.; Schwarzschild, M.A.;Van der Schyf, C.J.; Castagnoli, N. Inhibition of monoamine oxidase B byselective adenosine A2A receptor antagonists. Bioorg. Med. Chem., 2003, 11, 1299-1310. (Pubitemid 36293525)
150. Pretorius, J.; Malan, S.F.; Castagnoli, N.Jr.; Bergh, J.J.; Petzer, J.P. Dualinhibition of monoamine oxidase B and antagonism of the adenosine A2Areceptor by (E, E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg. Med.Chem., 2008, 16, 8676-8684.
151. (a) Hung, A.Y.; Haass, C.; Nitsch, R.M.; Qiu, W.Q.; Citron, M.; Wurtman, R.J.; Growdon, J.H.; Selkoe, D.J. Activation of protein kinase C inhibitscellular production of the amyloid beta-protein. J. Biol. Chem., 1993, 268, 22959-22962 (Pubitemid 23327996)
152. (b) Bandyopadhyay, S.; Goldstein, L.E.; Lahiri, D.K.; Rogers, J.T. Role of the APP non-amyloidogenic signaling pathway and targetingalpha-secretase as an alternative drug target for treatment of Alzheimer'sdisease. Curr. Med. Chem., 2007, 14, 2848-2864 (Pubitemid 350201652)
153. (c) Bar-Am, O.; Amit, T.;Weinreb, O.; Youdim, M.B.H.; Mandel, S. Propargylamine containingcompounds as modulators of proteolytic cleavage of amyloid-beta proteinprecursor: involvement of MAPK and PKC activation. J. Alzheimer's Dis., 2010, 21, 361-371.
154. Yogev-Falach, M.; Amit, T.; Bar-Am, O.; Weinstock, M.; Youdim, M.B.H.Involvement of MAP kinase in the regulation of amyloid precursor proteinprocessing by novel cholinesterase inhibitors derived from rasagiline. FASEBJ., 2002, 16, 1674-1676.
155. Hu, M.K.; Liao, Y.F.; Chen, J.F.; Wang, B.J.; Tung, Y.T.; Lin, H.C.; Lee, K.P. New 1, 2, 3, 4-tetrahydroisoquinoline derivatives as modulators ofproteolytic cleavage of amyloid precursor proteins. Bioorg. Med. Chem., 2008, 16, 1957-1965.
156. Murata, M.; Hasegawa, K.; Kanazawa, I.; Murata, M.; Hasegawa, K.;Kanazawa, I. The Japan Zonisamide on, P. D. S. G. Zonisamide improvesmotor function in Parkinson disease: a randomized, double-blind study.Neurology, 2007, 68, 45-50. (Pubitemid 46058551)
157. Biton, V. Clinical pharmacology and mechanism of action of zonisamide.Clin. Neuropharmacol., 2007, 30, 230-240. (Pubitemid 47356720)
158. Asanuma, M.; Miyazaki, I. Protective effects of a novel anti-parkinsonianagent zonisamide on dopamine quinone-related neurotoxicity. Society forNeuroscience Program Nol 158, 2007, 1.
159. Tokumaru, J.; Ueda, Y.; Yokoyama, H.; Nakajima, A.; Doi, T.; Mitsuyama, Y.; Ohya-Nishiguchi, H.; Kamada, H. In vivo evaluation of hippocampalanti- oxidant ability of zonisamide in rats. Neurochem. Res., 2000, 25, 1107-1111.
160. Sonsalla, P. K.; Wong, L.-Y.; Winnik, B.; Buckley, B. The antiepileptic drugzonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinicalrelevance. Exp. Neurol., 2010, 221, 329-334.
161. Binda, C.; Aldeco, M.; Mattevi, A.; Edmondson, D.E. Interactions ofmonoamine oxidases with the antiepileptic drug zonisamide: Specificity ofinhibition and structure of the human monoamine oxidase B complex. J.Med. Chem., 2011, 54, 909-912.
162. Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.;Kuiperi, C.; O'Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E.Acute treatment with the PPARg agonist pioglitazone and ibuprofen reducesglial inflammation and Ab 1-42 levels in APPV7171 transgenic mice. Brain, 2005, 128, 1442-1453. (Pubitemid 40826196)
163. Breidert, T.; Callebert, J.; Heneka, M.T.; Landreth, G.; Launay, J.M.; Hirsch, E.C. Protective action of the peroxisome proliferator-activated receptor-γagonist pioglitazone in a mouse model of Parkinson's disease. J.Neurochem., 2002, 82, 615-624. (Pubitemid 34831499)
164. Dehmer, T.; Heneka, M.T.; Sastre, M.; Dichgans, J.; Schultz, J.B. Protectionby pioglitazone in the MPTP model of Parkinson's disease correlates withIkBa induction and block of NFkB and iNOS activation. J. Neurochem., 2004, 88, 494-501. (Pubitemid 38084565)
165. Quinn, L.P.; Crook, B.; Hows, M.E.; Vidgeon-Hart, M.; Chapman, H.;Upton, N.; Medhurst, A.D.; Virley, D.J. The PPARγ agonist pioglitazone iseffective in the MPTP mouse model of Parkinson's disease throughinhibition of monoamine oxidase B. Br. J. Pharmacol., 2008, 154, 226-233. (Pubitemid 351620404)
166. (a) Combs, C.K.; Johnson, D.E.; Karlo, J.C.; Cannady, S.B.; Landreth, G.E.Inflammatory mechanisms in Alzheimer's disease: inhibition of betaamyloid-stimulated proinflammatory responses and neurotoxicity byPPARgamma agonists. J. Neurosci., 2000, 2, 558-567 (Pubitemid 30225558)
167. (b) Inestrosa, N.C.;Godoy, J.A.; Quintanilla, R.A.; Koenig, C.S.; Bronfman, M. Peroxisomeproliferator-activated receptor gamma is expressed in hippocampal neuronsand its activation prevents beta-amyloid neurodegeneration: role of Wntsignalling. Exp. Cell Res., 2005, 304, 91-104. (Pubitemid 40227422)
168. Recent advances in QSAR studies. Methods and applications. In: Challengesand Advances in Computational Chemistry and Physics, 1st ed., vol. 8.;Puzyn, T.; Leszczynski, J.; Cronin, M.T.D. Eds.; Springer: Dordrecht, TheNetherlands, 2010.
169. (a) 3D QSAR in drug design: recent advances. In: Perspectives in drugdiscovery and design, vol. 12-14; Kubinyi, H.; Folkers, G.; Martin, Y.C.Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1998
170. (b) 3DQSAR in drug design: ligand-protein interactions and molecular similarity, vol. 2; Kubinyi, H.; Folkers, G.; Martin, Y.C. Eds.; Kluwer AcademicPublishers: Dordrecht, The Netherlands, 1998.
171. Pharmacophores and Pharmacophore Searches. In: Methods and Principlesin Medicinal Chemistry, vol. 32, Langer, T.; Hoffmann, R.D. Eds.; Wiley-VCH: New York, 2006.